Across TCGA pan-cancer cohorts, UROS mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated UROS data layer compared with 22 for mass-spec protein.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher UROS mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated UROS expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

PDAC, LSCC, and HNSC are the cancer types where UROS mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	III,IV	0.302	0.915	.002	24	view →
LSCC	DFS	Tertile	II,III,IV	0.484	0.892	.006	15	view →
HNSC	DFS	Tertile	III,IV	1.000	0.880	.010	4	view →
LUAD	DFS	Tertile	All	0.852	0.418	.015	4	view →
UCEC	DFS	Quartile	All	1.000	0.881	.022	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: UROS tumor-vs-normal RNA expression · all UROS data types